Skip to main content

Freedom of information requests

FOI 2914 2022/23

Melanoma & RCC

Published 30 October 2023

Melanoma & RCC

Questions

Q1. How many patients have been treated in the past 3 months with the following agents for renal cell carcinoma


Q2. How many patients have been treated in the past 3 months with the following agents for melanoma (any stage):

Response

Ans 1

 

Drug

QE

HGS

  • Avelumab + Axitinib

12

0

  • Axinitib

0

0

  • Cabozantinib

19

0

  • Everolimus

16

0

  • Lenvatinib + Everolimus

0

0

  • Nivolumab + Cabozantinib

1

0

  • Nivolumab + Ipilimumab

39

0

  • Nivolumab 

192

0

  • Other active systemic anti-cancer therapy

0

0

  • Palliative care only

0

0

  • Pazopanib

4

0

  • Pembrolizumab + Axitinib

0

0

  • Pembrolizumab + Lenvatinib

7

2

  • Pembrolizumab monotherapy

206

0

  • Radiotherapy only

0

0

  • Sunitinib

17

0

  • Temsirolimus

0

0

  • Tivozanib

3

0

 

Ans 2

None

 

Please note – this response covers four hospitals.

QE = Queen Elizabeth Hospital Birmingham

HGS = Heartlands, Good Hope and Solihull Hospitals